From Transplant to Transcriptional Reprogramming: How Erythroid Gene Regulation Is Transforming Curative Therapy in Sickle Cell Disease

Sickle cell disease (SCD) remains a major global health burden and one of the most prevalent inherited blood disorders worldwide. For decades, hematopoietic stem cell transplantation (HSCT) has long been the only established curative therapy; however, donor scarcity, graft-versus-host disease, conditioning-related toxicity, and limited accessibility have restricted its use, prompting the search for donor-independent curative approaches. This review explores how advances in erythroid gene regulation and transcriptional reprogramming are reshaping curative therapy for SCD by tracing the evolution from HSCT to precision gene-based interventions. A deeper understanding of hemoglobin switching and the regulatory roles of erythroid transcription factors, including BCL11A, KLF1, ZBTB7A, and MYB, has enabled strategies that reactivate fetal hemoglobin or seek to directly correct the pathogenic HBB mutation. Gene addition, CRISPR-Cas9 gene editing, and emerging base- and prime-editing technologies offer autologous, donor-independent alternatives to transplantation, with early clinical studies demonstrating durable disease modification and encouraging therapeutic outcomes. Advances in genome editing, delivery systems, and long-term safety monitoring will determine the widespread clinical adoption of these therapies, particularly in low- and middle-income countries where the burden of SCD is greatest. Collectively, these advances demonstrate that while HSCT established the curability of SCD, erythroid gene regulation and transcriptional reprogramming are now redefining the concept of cure and expanding the potential for donor-independent curative therapy.